Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia
- PMID: 3798566
- DOI: 10.1177/030089168607200503
Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia
Abstract
The in vitro effect of adriamycin (ADR) and lonidamine alone and in combination, at 37 degrees C and 43 degrees C, was investigated on murine leukemia P388 sensitive (P388/S) and resistant (P388/ADR) to adriamycin. The sensitive and the resistant cells were exposed in vitro with and without the drugs for 1 h at 37 degrees C and 43 degrees C. These cells were inoculated ip (10(6) cells/mouse) into groups of BDF1 mice. Cytotoxic effect of the treatment was assessed on the basis of percentage increase in life span (% ILS) of these animals, compared to the animals receiving cells which did not receive any treatment but exposed only to 37 degrees C for 1 h. It was observed that exposure of P388/ADR cells to lonidamine or adriamycin alone at 43 degrees C for 1 h resulted in greater cell kill, thus enhancing the % ILS of the experimental animals receiving those cells, compared to that of mice receiving the cells exposed to the same drugs for 1 h at 37 degrees C. However, the combination of lonidamine (0.02 mM) and adriamycin (10 micrograms/ml) at 43 degrees C for 1 h showed more than a synergistic effect, resulting in a % ILS of 120. Similar results were seen in the case of P388/S; however, the observations pertaining to P388/ADR are encouraging, since the mode of treatment has reversed the acquired resistance of P388 leukemia cells to adriamycin.
Similar articles
-
Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.Neoplasma. 1986;33(2):217-23. Neoplasma. 1986. PMID: 3713924
-
Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.Cancer Res. 1986 Jun;46(6):2978-83. Cancer Res. 1986. PMID: 3698020
-
Evaluation of quinidine effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.Sel Cancer Ther. 1990 Summer;6(2):93-102. doi: 10.1089/sct.1990.6.93. Sel Cancer Ther. 1990. PMID: 2367755
-
Differential agglutination of P388 adriamycin-sensitive and P388 adriamycin-resistant leukemia cells.Oncology. 1983;40(3):202-4. doi: 10.1159/000225726. Oncology. 1983. PMID: 6843944
-
Lonidamine, a new approach to cancer therapy.Oncology. 1984;41 Suppl 1:2-6. doi: 10.1159/000225878. Oncology. 1984. PMID: 6371644 Review.
Cited by
-
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.Breast Cancer Res Treat. 1992;24(1):27-34. doi: 10.1007/BF01832355. Breast Cancer Res Treat. 1992. PMID: 1463869
-
Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.Br J Cancer. 1998;77(3):434-9. doi: 10.1038/bjc.1998.69. Br J Cancer. 1998. PMID: 9472640 Free PMC article.
-
Phase II study of lonidamine in metastatic breast cancer.Br J Cancer. 1989 Feb;59(2):251-3. doi: 10.1038/bjc.1989.51. Br J Cancer. 1989. PMID: 2930690 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials